Most PI firm budgets treat marketing as an expense. It sits on the cost side of the ledger, managed as a necessary outlay that needs to be minimized, justified, and — when times are tight — cut.
This is an accounting convention. It is also a strategic mistake.
When you treat lead generation as a cost line, the instinct is to reduce it. When you treat it as a revenue investment, the instinct is to optimize it. Those two instincts lead to very different firms over a five-year horizon.
The Conceptual Shift That Changes Everything
A cost is something you pay to operate. A revenue investment is something you commit capital to in order to produce a measurable return. The difference is not semantic — it changes how you make decisions, how you evaluate performance, and how you have conversations with partners about the marketing budget.
When marketing is a cost, the budget conversation sounds like: “How much do we need to spend to stay competitive?” The answer is usually “about the same as last year, maybe a little more.” It is a maintenance framing.
When marketing is a revenue investment, the conversation sounds like: “Given our current cost per case and average case value, what is the optimal allocation that maximizes return?” That is a growth framing. And it is only possible if you have the data to support it.
Why Most PI Firms Can't Make This Shift
The reason most PI firms treat marketing as a cost line is not because they lack ambition or strategic thinking. It is because they lack the measurement infrastructure to treat it as anything else.
To treat lead generation as a revenue investment, you need to know the return on that investment. That requires knowing your cost per signed case by vendor, your case value by source, and how both change over time. Most firms have at best a rough sense of these numbers — and “rough sense” is not sufficient for investment-grade decisions.
If you cannot demonstrate, with specific numbers, that $50,000 spent with Vendor A produced $X in signed case value at a cost of $Y per case, you cannot make the investment argument. You can only make the cost argument. And cost arguments lead to budget conversations about minimum viable spend rather than optimal allocation.
The vendor reports problem
Many firms try to answer the ROI question using vendor-provided reports. This approach has a fundamental conflict of interest: vendors report on their own performance using metrics that make them look good. Cost per lead is a natural choice because it measures media buying efficiency — something vendors can control — rather than case conversion, which involves the firm's intake team and case criteria.
Vendor reports can tell you how many leads arrived and at what cost. They cannot tell you how many of those leads became signed cases, because that data lives in your case management system, not the vendor's dashboard. The metric that matters for evaluating a revenue investment — cost per case — is exactly the metric vendors have no incentive to help you calculate.
What Investment-Grade Marketing Measurement Looks Like
Treating lead generation as a revenue investment requires three measurement capabilities that most PI firms have not yet built.
Return on marketing spend by source
The core metric of investment-grade marketing is return on marketing spend — not cost per lead, but cost per case by source, and ideally revenue per marketing dollar spent once settlement data is available.
For a firm spending $300,000 per month across eight vendors, this means knowing that Vendor A produced 22 cases at $4,500 per case, Vendor B produced 14 cases at $6,200 per case, and Vendor C produced 31 cases at $3,100 per case. That data tells you where to increase allocation, where to negotiate, and where to cut — not based on gut feeling, but based on measured return.
Marginal return analysis
Investment-grade thinking also asks: what happens to return when I increase the allocation? Some vendors can scale — if you double their budget, lead volume and case output roughly double. Others hit a ceiling quickly, and additional spend produces diminishing returns.
Understanding marginal return by vendor is the difference between knowing where your best dollars are going and knowing where your next best dollar should go. The firms that have this data make allocation decisions with a confidence their competitors cannot match.
Portfolio-level performance
No single vendor should be evaluated in isolation. The question is not just “is Vendor A performing well?” — it is “is Vendor A performing well relative to the other capital deployment options in our vendor portfolio?”
This portfolio framing changes how you think about allocation. A vendor with a cost per case of $4,200 might look fine until you realize that Vendor B is consistently delivering at $2,800 and could absorb more budget. The comparison is only visible when you have cost per case data across the entire portfolio.
The Budget Conversation That Becomes Possible
When you have investment-grade marketing measurement, the conversation with partners changes in a specific and important way.
Instead of defending the marketing budget — “we need to maintain our presence in the market, competitors are spending more, leads are more expensive than they used to be” — you can propose marketing investment with a projected return. “Our current vendor portfolio is producing signed cases at an average cost of $3,400. Our average case value is $47,000. At current allocation rates, increasing total marketing spend by $60,000 per month, directed toward our three highest-performing vendors, should produce 15 to 18 additional signed cases per month based on current conversion rates.”
That is an investment pitch. Partners respond to investment pitches very differently than to cost justifications. The conversation becomes collaborative rather than adversarial, and the marketing leader becomes a revenue strategist rather than a budget defender.
The Cases You Are Not Signing
There is a useful way to reframe the cost of not measuring marketing as a revenue investment. Every month you operate without cost per case data, you are likely underfunding at least one high-performing vendor and overfunding at least one underperforming vendor. The spread between those two errors is not trivial.
Imagine a vendor producing cases at $2,800 each who is getting $30,000 per month — generating roughly 10 to 11 cases. And another vendor charging $5,500 per case getting $40,000 per month — generating roughly 7 cases. Shifting $20,000 of allocation from the second vendor to the first produces 3 to 4 additional cases per month at the same total spend. Over a year, that is 36 to 48 signed cases from the same marketing budget.
Those are not hypothetical cases. They are cases your firm is not signing right now, because the data that would justify the reallocation does not exist in a form anyone can act on.
Cost Line Framing
- 'We need to maintain our market presence'
- 'Leads are more expensive than they used to be'
- Defensive, maintenance-oriented
- Partner sees expense to minimize
Revenue Investment Framing
- 'Our portfolio produces cases at $3,400 each'
- 'Increasing spend by $60K/mo should yield 15-18 more cases'
- Proactive, growth-oriented
- Partner sees investment with projected return
Starting the Shift
You do not need to overhaul your entire marketing operation to start treating lead generation as a revenue investment. You need one thing: cost per signed case by vendor, updated regularly. Everything else — portfolio comparisons, marginal return analysis, settlement value attribution — builds from that foundation.
The firms making this shift are not doing it with more spreadsheets. They are doing it with systems that connect marketing spend data to case management data automatically — so the metric they need is always current and always available, not assembled manually the week before the partner meeting.
The accounting ledger will still list marketing as a cost. But the firms that treat it as a revenue investment — and measure it accordingly — will make the kind of decisions that compound into a meaningful competitive advantage over time.